Unknown

Dataset Information

0

Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria.


ABSTRACT: The lack of therapeutic options to treat infections caused by multidrug-resistant (MDR) pathogens, especially Gram-negative bacteria, is apparent. Therefore, it is imperative to develop new strategies to address the problem of antimicrobial resistance. Repurposing non-antibiotic commercial drugs for antimicrobial therapy presents a viable option. We screened six anticancer drugs for their potential use in antimicrobial therapy. Here, we provide in vitro evidence that suggests feasibility to repurpose the anticancer drug mitomycin C against MDR Gram-negative bacteria. We also demonstrated that mitomycin C, etoposide and doxorubicin were affected by drug efflux in Pseudomonas aeruginosa. In combination with a tobramycin-ciprofloxacin antibiotic hybrid (TOB-CIP), the antibacterial activity of mitomycin C was enhanced against MDR clinical isolates of P. aeruginosa, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. In fact, 4 ?g/mL (3 ?M) TOB-CIP reduced the minimum inhibitory concentration of mitomycin C to ?1 ?g/mL against MDR Gram-negative bacteria, except A. baumannii. We showed that synergy was inherent to TOB-CIP and that neither tobramycin nor ciprofloxacin individually synergized with mitomycin C. Our finding supports identifying adjuvant partners for mitomycin C, such as TOB-CIP, to enhance suitability for antimicrobial therapy.

SUBMITTER: Domalaon R 

PROVIDER: S-EPMC6636613 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria.

Domalaon Ronald R   Ammeter Derek D   Brizuela Marc M   Gorityala Bala Kishan BK   Zhanel George G GG   Schweizer Frank F  

Frontiers in microbiology 20190710


The lack of therapeutic options to treat infections caused by multidrug-resistant (MDR) pathogens, especially Gram-negative bacteria, is apparent. Therefore, it is imperative to develop new strategies to address the problem of antimicrobial resistance. Repurposing non-antibiotic commercial drugs for antimicrobial therapy presents a viable option. We screened six anticancer drugs for their potential use in antimicrobial therapy. Here, we provide <i>in vitro</i> evidence that suggests feasibility  ...[more]

Similar Datasets

| S-EPMC10360068 | biostudies-literature
| S-EPMC6457190 | biostudies-literature
| S-EPMC7601562 | biostudies-literature
| S-EPMC3642096 | biostudies-literature
| S-EPMC10434301 | biostudies-literature
| S-EPMC3088195 | biostudies-literature
2008-02-26 | GSE7163 | GEO
| S-EPMC8389907 | biostudies-literature
2010-05-26 | E-GEOD-7163 | biostudies-arrayexpress
| S-EPMC8101105 | biostudies-literature